CVS Health mulling options, including possible break-up - Reuters
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
Morgan Stanley Reiterates Overweight Rating on CVS Health (CVS)
October 2, 2024 6:56 AM EDTMorgan Stanley analyst Erin Wright reiterated an Overweight rating and $65.00 price target on CVS Health (NYSE: CVS).
The analyst comments "Latest Hypothetical SOTP Suggests Upside, But Variables Remain: In light of a recent Reuters report (here) noting that the CVS Board may be considering potential options to break up CVS retail and insurance businesses, we detail our latest SOTP analysis, including key assumptions below. CVS declined to... More
Leerink Partners Reiterates Market Perform Rating on CVS Health (CVS)
October 1, 2024 6:28 AM EDTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating on CVS Health (NYSE: CVS).
The analyst comments "Bottom Line: Following our initial note highlighting the potential of CVS evaluating strategic alternatives including a break-up of the company (Initial CVS note; WSJ report) we wanted to include some quick views on the potential plusses and potential minuses of a breakup. This isn't meant to be comprehensive and is intentionally short form given the fluidity of the reported situation. But we thought it was important to highlight how this... More
Evercore ISI Reiterates Outperform Rating on CVS Health (CVS)
October 1, 2024 5:54 AM EDTEvercore ISI analyst Elizabeth Anderson reiterated an Outperform rating and $62.00 price target on CVS Health (NYSE: CVS).
The analyst comments "What happened? After the market close today, Reuters reported that CVS is exploring options, including a potential break-up of the company to... More
